On Tuesday, Guess?, Inc. (NYSE:GES)’s shares inclined 6.26% to $18.66.
Guess?, Inc. (GES) stated financial results for its first quarter ended May 2, 2015.
First Quarter Fiscal 2016 Highlights
- North American Retail revenues reduced 6%; retail comp sales counting e-commerce reduced 6% in U.S. dollars and 4% in constant currency
- European revenues reduced 14% in U.S. dollars and raised 8% in constant currency
- Asian revenues reduced 9% in U.S. dollars and 6% in constant currency
- North American Wholesale revenues reduced 5% in U.S. dollars and raised 1% in constant currency
- Earnings from operations of $4 million in Q1 fiscal 2016; contrast to loss from operations of $2 million in Q1 fiscal 2015
First Quarter Fiscal 2016 Results
For the first quarter of fiscal 2016, the Company recorded net earnings of $3.3 million, contrast to a net loss of $2.1 million for the first quarter of fiscal 2015. Diluted earnings per share was $0.04, contrast to diluted loss per share of $0.03 for the prior-year quarter, an enhance of $0.07 per share.
Total net revenue for the first quarter of fiscal 2016 reduced 8.4% to $478.8 million, from $522.5 million in the prior-year quarter. In constant currency, total net revenue was roughly flat contrast to the same prior-year period. Refer to the accompanying tables for a summary of the impact of foreign currency exchange rate fluctuations on the Company’s net revenue.
- The Company’s retail stores and e-commerce sites in North America generated revenue of $214.2 million in the first quarter of fiscal 2016, a 6.2% decrease from $228.3 million in the same period a year ago. Comparable store sales counting the results of our e-commerce sites for the first quarter of fiscal 2016 reduced 5.9% in U.S. dollars and 3.8% in constant currency contrast to the same period a year ago.
- Net revenue from the Company’s Europe segment reduced 13.7% to $137.4 million in the first quarter of fiscal 2016, from $159.2 million in the prior-year period. In constant currency, net revenue raised 7.5%.
- Net revenue from the Company’s Asia segment reduced 8.7% to $64.0 million in the first quarter of fiscal 2016, from $70.1 million in the prior-year period. In constant currency, net revenue reduced 6.0%.
Guess?, Inc. designs, markets, distributes, and licenses lifestyle collections of contemporary apparel and accessories for men, women, and children that reflect the American lifestyle and European fashion sensibilities. It operates through North American Retail, Europe, Asia, North American Wholesale, and Licensing segments.
RXi Pharmaceuticals Corp (NASDAQ:RXII)’s shares dropped -1.01% to $0.374.
RXi Pharmaceuticals Corp (RXII) declared that Dr. Pamela Pavco, RXi’s Chief Development Officer, will present at the 23rd World Congress of Dermatology (WCD). This six-day world congress will comprise in-depth presentations by world-class clinicians and/or investigators, dermatology forums for health professionals, patient advocacy and support forums and other plenary sessions.
On Tuesday, June 9, 2015 at 2:35 p.m. PDT, Dr. Pavco will present an overview of the Company’s dermal clinical program with RXI-109. The presentation, entitled “Update on Phase 2a Clinical Trial Results of RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars and Keloids,” will take place during the Free Communications session: FC-07 Wound Healing. The presentation will be accessible on the Company’s website at www.rxipharma.com about one hour after the presentation.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
At the end of Tuesday’s trade, The Carlyle Group LP (NASDAQ:CG)‘s shares dipped -4.91% to $49.16.
The Carlyle Group LP (CG) declared the pricing of an offering of 7,000,000 common units by Carlyle. The offering is predictable to close on June 5, 2015, subject to customary closing conditions. Citigroup and J.P. Morgan are serving as underwriters for the offering. Carlyle intends to use the net proceeds from the offering to purchase an equivalent number of outstanding Carlyle Holdings partnership units from existing unit holders, counting certain of its directors and executive officers. Accordingly, Carlyle will not retain any proceeds from the offering.
The offering of these securities is being made following an effective shelf registration statement. This offering will be made only by means of a prospectus. A copy of the prospectus, when accessible, may be obtained from: Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at (800) 831-9146, or J.P. Morgan, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department or by phone at (866) 803-9204.
The Carlyle Group LP is an investment firm specializing in direct and fund of fund investments. Within direct investments, it specializes in administration-led/ Leveraged buyouts, privatizations, divestitures, planned minority equity investments, structured credit, global distressed and corporate opportunities, small and middle market, equity private placements, consolidations and buildups, senior debt, mezzanine and leveraged finance, and venture and growth capital financings, seed/startup, early venture, emerging growth, turnaround, mid venture, late venture, PIPES.
Paychex, Inc. (NASDAQ:PAYX), ended its Tuesday’s trading session with -0.51% loss, and closed at $49.16.
Paychex, Inc. (PAYX) reduced 0.17 percent in May, bringing the national index to 100.65. Year over year the national index declined 0.49 percent. Moderating from last month, the drop in the national index brought the three-month growth rate to -0.18 percent. The East North Central region surpassed the West North Central to become the top-ranked regional index. Indiana regained the lead among states tracked by the index with the best one-month and 12-month growth rates. Among the metro areas measured by the index, Dallas continued to lead, while Washington, D.C. showed the most improvement.
The Paychex | IHS Small Business Index dropped 0.17 percent in May, reverting to its January 2015 level. While the national index is well below the level set throughout most of 2014, small businesses are expanding to be sure, but at a rate comprising with the growth seen in 2012,” said James Diffley, chief regional economist at IHS.
National Index
After holding onto the positive momentum of early 2015 in April, job gains slowed in May. At 100.65, the national index is at its lowest level of 2015 and 0.49 percent behind the job growth rate of May 2014.
Regional Employment
The East North Central overtook the West North Central for the top-ranked regional index position as the WNC had the lowest one-month growth rate for the second successive month. Up for the fourth straight month and the only region to improve in May, the Mountain index climbed to 100.80, growing 0.77 percent from February to May.
Paychex, Inc. provides payroll, human resource, insurance, and benefits outsourcing solutions for small to medium-sized businesses in the United States and Germany. The company offers payroll processing services that comprise the calculation, preparation, and delivery of employee payroll checks; production of internal accounting records and administration reports; preparation of federal, state, and local payroll tax returns; and collection and remittance of clients payroll obligations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
